Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request

Register


Add a topic or expert to your feed.

Following

Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

Experts
Topics
Project
On The Ground
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

search
Close Nav
Share this commentary on Close

MI Responds: Scott Gottlieb Confirmed as FDA Commissioner

commentary

MI Responds: Scott Gottlieb Confirmed as FDA Commissioner

May 9, 2017
Health PolicyFDA ReformDrug Development

I applaud both President Trump and the U.S. Senate on the confirmation of Dr. Scott Gottlieb as FDA Commissioner. At a time of both unprecedented scientific opportunity and rapidly evolving public health challenges, Dr. Gottlieb provides the FDA with principled and pragmatic leadership. His experience as a regulator, practicing physician, cancer survivor, and innovator will help the agency navigate the scientific challenges surrounding drug and medical device development and approval without losing sight of the real-world implications of the agency’s decisions for patients struggling with potentially life threatening conditions.

—Paul Howard, Senior Fellow and Director, Health Policy

By choosing Dr. Gottlieb to lead the FDA, President Trump has signaled his commitment to streamlining outdated drug development regulations and putting patients first. By confirming his appointment, the Senate has signaled that it understands the need for bold leadership at the agency as it helps innovators unlock the full potential of new technologies like gene therapy, address the nation’s growing opioid crisis, and maintain the nation’s preparedness for emerging threats like Ebola or pandemic flu.

Tom Coburn, Nick Ohnell Fellow and Advisor, Project FDA

MI Responds features real-time commentary from MI scholars on breaking news and developing issues. 

______________________

Paul Howard is a senior fellow and director of health policy at the Manhattan Institute. Follow him on Twitter here.

Dr. Tom Coburn is the Nick Ohnell Fellow at the Manhattan Institute and a former two-term U.S. Senator from Oklahoma.

Photo by Zach Gibson / Stringer
Saved!
Close